A New Balanitis Treatment Proposal Shows What Case Reports Can and Cannot Prove

Philip R. Cohen, a dermatologist affiliated with the University of California, San Diego and San Diego Family Dermatology, has a paper appearing in the October 2026 issue of the Journal of the American Academy of Dermatology arguing that mupirocin 2% ointment belongs in the treatment armamentarium for balanitis circumscripta plasmacellularis, better known as Zoon balanitis. The headline itself signals the genre: this is a call to add an option to a list, not the announcement of a trial result.

Zoon balanitis is a benign, chronic inflammatory condition of the glans penis that mostly affects uncircumcised men in midlife and beyond, producing shiny orange-red patches that can be mistaken for premalignant or infectious disease. Because it is uncommon and rarely dangerous, no randomized controlled trial has ever compared treatments for it head to head. The published record instead consists of decades of scattered case reports and small case series covering circumcision, topical corticosteroids, tacrolimus, imiquimod, and various lasers, each entering clinical use the same way this new proposal is arriving: one clinician's documented experience, published as evidence that other doctors can try the same thing.

That publication format matters for how much weight the claim can bear. A single-author paper in a journal's case-report or correspondence section is built to introduce an idea into circulation, not to establish it as superior to existing options. It cannot report a response rate across a meaningful sample, cannot compare mupirocin against corticosteroids or tacrolimus in the same patients, and cannot say how durable the effect is beyond whatever follow-up window the author happened to observe. What it can do is document that an inexpensive, widely available topical antibiotic, ordinarily prescribed for impetigo and other superficial skin infections, produced a favorable result in at least one documented case of Zoon balanitis.

The suggestion that mupirocin might work is not implausible on its own terms. Some clinicians have theorized that bacterial colonization under the foreskin contributes to the inflammation seen in Zoon balanitis, which would give an antibiotic ointment a plausible mechanism alongside its anti-inflammatory topical predecessors. Plausibility is not the same as proof, though, and JAAD readers encountering this piece are being offered a hypothesis worth testing in more patients, not a new standard of care.

For now, the paper's real contribution is narrower than its title suggests: it adds mupirocin to a list of options a dermatologist might reach for when first-line therapies fail or are contraindicated, alongside the corticosteroids, tacrolimus, and imiquimod that arrived in clinical practice by the same case-report route decades earlier. Whether it earns a permanent place on that list depends on studies this single paper was never designed to produce.